Clinical Trial

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies how well abemaciclib works in treating patients with ovarian or endometrial cancer that has an activation of the CDK4/6 pathway and that has come back (recurrent). Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving abemaciclib may work better for the treatment of recurrent ovarian and endometrial cancer.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2020-07-13; most recent amendment 2026-07-16.
Status change: Not Yet Recruiting → Recruiting 2020-12-02
Trial Details
NCT Number NCT04469764
Lead Sponsor Jonsson Comprehensive Cancer Center
Collaborators: Eli Lilly and Company
Conditions Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Enrollment 32 participants
Start Date 2020-10-16
Primary Completion 2027-07-01 (estimated)
Study Completion 2028-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-17